Efficacy of infliximab in treatment of refractory panuveitis associated with Behçet disease
Introduction. Behcet disease (BD) is a chronic multi-system disorder with manifestations in the ocular, urological, articular, and vascular systems. Tumor necrosis factor alpha is believed to play a pivotal role in BD. Therapeutic blockade of its activity by infliximab is a novel therapeutic approac...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Serbian Medical Society
2017-01-01
|
| Series: | Srpski Arhiv za Celokupno Lekarstvo |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0370-8179/2017/0370-81791700103Z.pdf |
| _version_ | 1818461959806255104 |
|---|---|
| author | Živković Maja Zlatanović Marko Zlatanović Gordana Jakšić Vesna Hristov Aleksandra Jovanović Svetlana |
| author_facet | Živković Maja Zlatanović Marko Zlatanović Gordana Jakšić Vesna Hristov Aleksandra Jovanović Svetlana |
| author_sort | Živković Maja |
| collection | DOAJ |
| description | Introduction. Behcet disease (BD) is a chronic multi-system disorder with manifestations in the ocular, urological, articular, and vascular systems. Tumor necrosis factor alpha is believed to play a pivotal role in BD. Therapeutic blockade of its activity by infliximab is a novel therapeutic approach and has successfully led to remission of the disease. The aim is to report two cases of refractory BD-associated panuveitis (PU) treated with infliximab. The patients were followed for 12 months. The main therapy assessment parameters were the best corrected visual acuity (BCVA) in the better eye, slit lamp and fluorescein angiography (FAG) from baseline findings and from the final examination. Case outline. A male patient (45 years old, 25 years of BD history) and a female patient (45 years old, 15 years of BD history), both with posterior synechia, 3+ flare and complicated cataract, while the female also had hypopyon, were treated with infliximab administered at the dose of 5 mg/kg at weeks 0, 2, 6, and 14. The results for the male patient were as follows (baseline vs. the final examination): BCVA – 0.5 vs. 0.8; cellular reaction – 3+ vs. 1+; FAG – 1/2 vs. 0. The results for the female patient were as follows: BCVA – 0.1 vs. 0.3; FAG – 2/3 vs. 0. After 12 months, relapses or side-effects were not observed. Conclusion. Infliximab is an effective and promising drug in treating refractory BD-associated PU. It promptly reduces acute symptoms of PU, but it still remains to be seen if a long-term remission in a great number of patients will be achieved. |
| first_indexed | 2024-12-14T23:54:26Z |
| format | Article |
| id | doaj.art-0bc415c52ae343bd8d4f91654eee5b39 |
| institution | Directory Open Access Journal |
| issn | 0370-8179 2406-0895 |
| language | English |
| last_indexed | 2024-12-14T23:54:26Z |
| publishDate | 2017-01-01 |
| publisher | Serbian Medical Society |
| record_format | Article |
| series | Srpski Arhiv za Celokupno Lekarstvo |
| spelling | doaj.art-0bc415c52ae343bd8d4f91654eee5b392022-12-21T22:43:09ZengSerbian Medical SocietySrpski Arhiv za Celokupno Lekarstvo0370-81792406-08952017-01-0114511-1263563810.2298/SARH161216103Z0370-81791700103ZEfficacy of infliximab in treatment of refractory panuveitis associated with Behçet diseaseŽivković Maja0Zlatanović Marko1Zlatanović Gordana2Jakšić Vesna3Hristov Aleksandra4Jovanović Svetlana5Clinical Center Niš, Eye Clinic, NišClinical Center Niš, Eye Clinic, NišClinical Center Niš, Eye Clinic, NišSchool of Medicine, BelgradeEye Clinic “Maja”, NišClinical Center Kragujevac, Eye Clinic, KragujevacIntroduction. Behcet disease (BD) is a chronic multi-system disorder with manifestations in the ocular, urological, articular, and vascular systems. Tumor necrosis factor alpha is believed to play a pivotal role in BD. Therapeutic blockade of its activity by infliximab is a novel therapeutic approach and has successfully led to remission of the disease. The aim is to report two cases of refractory BD-associated panuveitis (PU) treated with infliximab. The patients were followed for 12 months. The main therapy assessment parameters were the best corrected visual acuity (BCVA) in the better eye, slit lamp and fluorescein angiography (FAG) from baseline findings and from the final examination. Case outline. A male patient (45 years old, 25 years of BD history) and a female patient (45 years old, 15 years of BD history), both with posterior synechia, 3+ flare and complicated cataract, while the female also had hypopyon, were treated with infliximab administered at the dose of 5 mg/kg at weeks 0, 2, 6, and 14. The results for the male patient were as follows (baseline vs. the final examination): BCVA – 0.5 vs. 0.8; cellular reaction – 3+ vs. 1+; FAG – 1/2 vs. 0. The results for the female patient were as follows: BCVA – 0.1 vs. 0.3; FAG – 2/3 vs. 0. After 12 months, relapses or side-effects were not observed. Conclusion. Infliximab is an effective and promising drug in treating refractory BD-associated PU. It promptly reduces acute symptoms of PU, but it still remains to be seen if a long-term remission in a great number of patients will be achieved.http://www.doiserbia.nb.rs/img/doi/0370-8179/2017/0370-81791700103Z.pdfBehçet diseaseTNF-αinfliximabretinalvasculitispanuveitis |
| spellingShingle | Živković Maja Zlatanović Marko Zlatanović Gordana Jakšić Vesna Hristov Aleksandra Jovanović Svetlana Efficacy of infliximab in treatment of refractory panuveitis associated with Behçet disease Srpski Arhiv za Celokupno Lekarstvo Behçet disease TNF-α infliximab retinalvasculitis panuveitis |
| title | Efficacy of infliximab in treatment of refractory panuveitis associated with Behçet disease |
| title_full | Efficacy of infliximab in treatment of refractory panuveitis associated with Behçet disease |
| title_fullStr | Efficacy of infliximab in treatment of refractory panuveitis associated with Behçet disease |
| title_full_unstemmed | Efficacy of infliximab in treatment of refractory panuveitis associated with Behçet disease |
| title_short | Efficacy of infliximab in treatment of refractory panuveitis associated with Behçet disease |
| title_sort | efficacy of infliximab in treatment of refractory panuveitis associated with behcet disease |
| topic | Behçet disease TNF-α infliximab retinalvasculitis panuveitis |
| url | http://www.doiserbia.nb.rs/img/doi/0370-8179/2017/0370-81791700103Z.pdf |
| work_keys_str_mv | AT zivkovicmaja efficacyofinfliximabintreatmentofrefractorypanuveitisassociatedwithbehcetdisease AT zlatanovicmarko efficacyofinfliximabintreatmentofrefractorypanuveitisassociatedwithbehcetdisease AT zlatanovicgordana efficacyofinfliximabintreatmentofrefractorypanuveitisassociatedwithbehcetdisease AT jaksicvesna efficacyofinfliximabintreatmentofrefractorypanuveitisassociatedwithbehcetdisease AT hristovaleksandra efficacyofinfliximabintreatmentofrefractorypanuveitisassociatedwithbehcetdisease AT jovanovicsvetlana efficacyofinfliximabintreatmentofrefractorypanuveitisassociatedwithbehcetdisease |